-
-
-
-
-
-
-
Oppenheimer on Coherus Biosciences (CHRS): 'We see potential for CHRS shares to build on recent gains'
-
-
-
-
-
-
-
Maxim Group Upgrades Coherus Biosciences (CHRS) to Buy, PT $4
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Tops Q4 EPS by 2c
-
-
-
-
-
-
-
Baird Reiterates Outperform Rating on Coherus Biosciences (CHRS)
-
-
-
-
443,923 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

